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ABSTRACT 
Red blood cell (RBC) alloimmunisation is a common problem in transfused patients because of 
the possibility of haemolytic reaction and limited availability of compatible blood. In high-
income countries, pre-transfusion antibody screening is performed routinely. In Ghana, patients 
are transfused with ABO Rh ‘D’ compatible blood without screening for immune antibodies. We 
therefore studied the prevalence and specificities of RBC antibodies in transfused patients at 
Komfo Anokye Teaching hospital, Ghana. The study was cross-sectional, involving previously 
transfused patients who required another transfusion. Participants’ basic data on demography 
and transfusion history were recorded.  Blood samples were screened and subsequently typed for 
RBC antibodies using a column gel agglutination tes. A total of 106 transfused patients, 52 male 
and 54 females were enrolled. The patients had previously received a median of 4 RBC units 
(range 1-14). Of these, ten patients (9.4%) had 11 RBC alloantibodies, whose specificities were 2 
anti-K; 2 anti-C; one each of anti-D, -E, -M, and -S; and 3 were pan-reactive. The number of 
transfusion episodes was significantly associated with the rate of alloimmunisation (p=0.000). In 
conclusion the overall alloimmunisation rate in the study was 9.4% and this was significantly 
associated with increasing number of transfusion episodes. Antibodies were mainly directed 
against antigens in the Rhesus system and K antigen. We recommend that antibody screening be 
incorporated into routine pre-transfusion testing procedures in Ghana. 
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INTRODUCTION 
Transfusion therapy is vital in the management 
of patients with haematologic disorders and 
malignancies (Hoffbrand et al., 2005). For 
these patients, it is a life-saving intervention as 
they are often chronically anaemic after chemo-
therapy and/or radiotherapy or usually require 
transfusion during illness. Although transfusion 
is life-saving, the development of antibodies 
against transfused foreign red blood cell (RBC) 
antigens (alloimmunisation) is one of the main 
risks associated with blood transfusion. 
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The incidence of alloimmunisation is reported 
to be up to about 60% in chronically transfused 
patients which generally include patients with 
haemoglobinopathies, haematologic malignan-
cies, organ transplant recipients and patients 
with renal failure (Schonewille et al., 1999; 
Angulo and Lima, 1999; Rosse et al., 1990). In 
other less transfused groups, alloimmunisation 
is between 1-10%. The prevalence depends 
largely on how often antibody screening and 
identification were performed (Alves et al., 
2012 ; Cheng et al., 2012 ; Schonewille t al., 
2006 ;  Santos et al., 2007; Melanie and Shul-
man, 2005 ; Aygun et al., 2002). 
 
Factors such as number and frequency of trans-
fusions (a measure of foreign antigen expo-
sure), ethnic differences between recipient and 
donor (Gader et al., 2008; Shaz et al., 2008), 
immunogenicity of RBC antigens, recipient’s 
sex (Murao and Viana, 2005), age (Winters t 
al., 2001), genetics (Noizat-Pirenne et al., 
2006; Higgins and Sloan, 2008) and underlying 
disease (Bauer et al., 2007) have been found to 
influence alloimmunisation risk. 
 
The risk of alloimmunisation increases with 
higher number of transfusions, however in 
multi-transfused patients most antibodies are 
formed after the first transfusions (Fluit e al., 
1990; Schonewille et al., 1999; Zalpuri et al., 
2012). Chronically transfused patients have 
about five times an increased risk of developing 
multiple antibodies (Schonewille t al., 2006) 
and are prone to developing autoantibodies 
which can lead to increased destruction of pa-
tients own red cells (Young et al., 2004). The 
most frequently encountered RBC antibodies 
are formed against the Rhesus and Kell blood 
group antigens (Schonewille et al., 1999; Hed-
dle et al., 1995; Seyfried and Walewska, 1990).  
  
In most high-income countries, patients are 
routinely tested for the presence of clinically 
important RBC antibodies before each transfu-
sion event. Once an antibody is detected, the 
transfusion recipient is given compatible blood 
that is lacking the corresponding antigen(s), to 
prevent haemolytic transfusion reactions. In 
addition, a pre-emptive antigen (Rh/K) match-
ing transfusion policy is often applied for 
chronically transfused patients and women in 
their (pre-) reproductive ages to reduce alloim-
munisation.  
 
In Ghana however, pre-transfusion screening 
involves only ABO and Rh “D” grouping and 
ABO compatibility testing, while antibody 
screening is not performed. To our best knowl-
edge, no studies have been performed, address-
ing post-transfusion alloimmunisation among 
the Ghanaian population. As a result, not much 
is known about patients’ antibody status and 
the effect of transfusion, despite the fact that 
alloimmunisation can significantly complicate 
transfusion therapy. The aim of this study was 
to determine the prevalence and specificities of 
RBC alloantibodies in previously transfused 
patients with different clinical conditions at 





The study was conducted at Komfo Anokye 
Teaching Hospital (KATH), in Kumasi, Ghana. 
Participants were recruited from the Medical, 
Dialysis, Oncology, Child Health, Surgery and 
Accident/Emergency Units of the hospital. 
KATH is the second largest and referral hospi-
tal in Ghana, serving five regions in the North-
ern sector of the country. It also provides spe-
cialized care to patients from neighbouring 
countries such as Burkina Faso, Togo, etc. 
 
Study population 
The study population included all patients over 
2 years of age, with a transfusion request and 
with at least one previous blood transfusion 
episode. Written informed consent was ob-
tained from participants 18 years and older and 
from guardians of those under 18 years.  
 
Inclusion criteria 
Patients over 2 years of age, with a transfusion 
request and with at least one previous blood  
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Patients below two years and patients who had 




Participants’ basic demographic features, num-
ber of transfusions, last transfusion episodes, 
clinical history and blood component requested 
were retrieved from patients’ medical records 
and recorded on a questionnaire. Whole blood 
samples (5ml) were obtained from consenting 
patients for ABO, Rh “D” grouping and anti-
body screening. ABO and Rh D blood grouping 
were performed using a manual tube method 
with monoclonal antisera A, B and D. Antibody 
screening and identification were performed at 
the Komfo Anokye Transfusion Medicine Unit 
(KA-TMU), using a three cell screen panel 
(Diacell I, II and III, DiaMed, Diamed Switzer-
land) in a low ionic strength indirect (LISS) 
anti-globulin test (Diamed Gel system, Dia-
Med-ID, Switzerland). Antibody identification 
was performed on all screen-positive samples 
using an extended 11-cell panel in LISS 
(DiaMed, Switzerland). Antibody specificities 
that could not be identified with the LISS tech-
nique were subjected to further testing with 
enzyme (papain)-enhanced cards, also from 




Ethical approval was obtained from the Com-
mittee on Human Research, Publication and 
Ethics, (CHRPE), School of Medical Sciences, 
Kwame Nkrumah University of Science and 
Technology in Kumasi, Ghana. 
 
Statistical Analysis 
Data were analyzed using SPSS version 16 for 
windows. Descriptive statistics were performed 
to summarize the patients’ demographic and 
transfusion information. Chi square tests were 
performed to determine any possible associa-
tion between factors (e.g. age, sex, number of  
previous transfusion episodes, disease groups) 
that may influence the outcome variable of in-
terest (prevalence rate of alloimmunisation). 
 
RESULTS 
Between January and September 2013, a total 
of 106 consecutive patients (52 males and 54 
females, Mean age 43.2±20.3 years, range 2-90 
years) who had received at least one transfusion 
were recruited from 6 different clinical wards 
of KATH for antibody investigation. The high-
est proportion of samples screened was from 
the Medical (35.2%) and surgical units (30.2%) 
(Table 1). Almost 40% of patients had malig-
nant disorders or renal disease. (Table 2). The 
patients had previously experienced a median 
of 4 RBC transfusion episodes (range 1-14; 
total 476) (Table 3). The current most frequent 
blood component requested was whole blood, 
while whole blood was issued in more than 
80% of cases of a packed cell request (Table 3). 
The proportions of ABO blood groups of the 
patients were 52.7% O, 25.9% A, 19.1% B and 
2.3% AB and 97.2% were Rh “D” positive. 
 
In 10 (9.4%) patients (median age 42.5years, 
range 13-60 years; male to female ratio 1:1), a 
total of 11 RBC antibodies were detected. Of 
these, 8 had clear specificity and 3 were pan-
reactive alloantibodies (Table 4). One immu-
nized patient (female with anti-K) had experi-
enced a single previous transfusion episode, 8 
patients had received 3-6, and one patient 10 
transfusion episodes, before antibody detection. 
There was a strong statistical association be-
tween the number of transfusion episodes and 
the rate of alloimmunisation (p=0.000), while 
other demographic features, age (p=0.983), 
gender (p= 0.765) and clinical diagnosis 




This was a pilot cross-sectional study under-
taken to determine the prevalence and specifici-
ties of RBC alloantibodies in Ghanaian patients 
who received blood transfusions at KATH. Our 
results showed that 9.4% of patients were allo- 
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Table 1: Proportion of patients from the various hospital units 
  Total                                                                          106                  100 
Hospital Units Number                           (%) 
Medicine 38 (35.8) 
Surgery 32 (30.2) 
Accident and Emergency 7 (6.6) 










Table 2: Disease types of patients and alloimmunisation characteristics 







    (n) 
Patients 
with RBC 
antibodies            





risk per unit 
transfused (%) 
Malignancy 23 (21.7) 121 2 8.7         1.7 
Renal disease 18 (17.0) 82 3 16.7         3.3 
Infectious diseases 16 (15.1) 71 2 12.5         2.3 
Anaemia (unspecified) 8 (7.5) 31 1 12.5         2.7 
Haemolytic condition* 8 (7.5) 29 0 0          0 
Bleeding 8 (7.5) 29 0 0          0 
Liver disease 4 (3.8) 12 0 0          0 
Others**  
21 (19.8) 101 2 9.5         3.0 
* Sickle cell disease, hepatosplenomegaly with anaemi  and Glucose-6-Phosphate dehydrogenase deficiency 
** Vocal cord paralysis, neuropathic ulcers, head injury, fistulae, fractures, burst abdomen, diabetes, immune compromised 
state and unknown clinical diagnosis. 
immunized, and the majority of antibodies were 
against antigens in the Rhesus blood group sys-
tem. The alloimmunisation risk was associated 
with increasing number of transfusion episodes. 
 
Our overall RBC alloimmunisation prevalence 
is in conformity with other published reports on  
patients receiving transfusion support for hae-
matological and other non haematological dis-
orders in both developing and developed coun-
tries (Natukunda et al., 2010; Shukla and 
Chaudhary, 1999). Most of our antibody speci-
ficities identified are similar to antibodies com- 
monly encountered and reported in other pub- 
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Table 3: Demographic and transfusion characteristics of RBC alloimmunized and non allo-
immunized patients 
Demographic and transfusion 





Median age in years (range) 





Sex ratio (F:M) 1:1 ~1:1 
Median previous transfusion episodes 
(range; total) 
4 (1-10; 41) 4 (1-14; 435) 
Current transfusion request: 
 Whole blood request (%) 5 (50) 50 (55.6) 
 Erythrocyte concentrate request (%) 5 (50) 40 (44.4) 
 Whole blood transfused (%) 8 (80) 84 (93.3) 
 
The number of whole blood and erythrocyte requests in non-immunized patients do not add up to 96, because for 6 pa-
tients the current request was for fresh frozen plasm  (n=2), platelet concentrate (n=3) and plasma + platelets (n=1).   
Table 4: Red blood cell antibody specificities identified in 10 immunized patients 
 Antibody specificity by blood group system          Number                              (%) 
D, C, E          1, 2, 1 (36.4) 
K              2 (18.1) 
M, S              1, 1 (18.1) 
Pan-reactive              3 (27.3) 
lished studies (Santos et al., 2007; Alves et al., 
2012), again confirming the high frequency of 
antibodies against Rhesus system antigens.  
 
Alloantibodies production in our study was 
mainly found in patients with more than two 
transfusion episodes but one patient developed 
an antibody after a single episode. This finding 
suggests that even a single non antigen-
matched transfusion may be enough to develop 
alloantibodies. One patient who had five trans-
fusion episodes produced two antibodies. This   
is consistent with a report of Schonewille et al. 
(2006), which found that multi-transfused pa-
tients are at high risk of developing multiple 
antibodies. The D antibody was unexpected 
since the patient was an Rh ‘D’ positive male. 
Similar findings have been reported by others 
(Chou et al., 2013; Natukunda et al., 2011). 
Although further D genotyping was not done, 
this patient may have a D variant, lacking cer-
tain epitopes to which the antibody was formed. 
 
Our findings suggest alloimmunisation is not  
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the fact that Ghana’s population is fairly ho-
mogenous. It is therefore necessary to expand 
the study to cover all the major regional and 
teaching hospitals in Ghana where chronically 
transfused patients are managed. We also rec-
ommend that antibody screening and identifica-
tion tests are incorporated in the routine pre-
transfusion testing procedures so that patients 
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